Difference between revisions of "Ribociclib (Kisqali)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Kinase inhibitors" to "") |
m |
||
| Line 16: | Line 16: | ||
==Also known as== | ==Also known as== | ||
*'''Code names:''' LEE011, LEE-011 | *'''Code names:''' LEE011, LEE-011 | ||
| − | *'''Brand | + | *'''Brand names:''' Kisqali, Kryxana |
==References== | ==References== | ||
| Line 25: | Line 25: | ||
[[Category:Protein expression-specific medications]] | [[Category:Protein expression-specific medications]] | ||
| − | + | [[Category:CDK4 inhibitors]] | |
| − | [[Category: | + | [[Category:CDK6 inhibitors]] |
[[Category:Breast cancer medications]] | [[Category:Breast cancer medications]] | ||
[[Category:FDA approved in 2017]] | [[Category:FDA approved in 2017]] | ||
Revision as of 15:41, 4 January 2021
General information
Class/mechanism: Cyclin-dependent kinase (CDK) 4 and 6 inhibitor. Ribociclib inhibits DNA synthesis and cancer cell growth by blocking activity of the cyclin D-CDK4/6 complex which regulates cell cycle progression and cellular proliferation by phosphorylating the retinoblastoma protein (pRb). Inhibiting pRb phosphorylation has been observed to lead to cell cycle arrest in the G1 phase.[1][2][3]
Route: PO
Extravasation: n/a
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 3/13/2017: Initial FDA approval in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
- 7/18/2018: FDA approval expanded in combination with an aromatase inhibitor for pre/perimenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy. (no longer limited to postmenopausal women)
Also known as
- Code names: LEE011, LEE-011
- Brand names: Kisqali, Kryxana